RxDoctor Payments Data

Twinkle Singh

Internal Medicine · Augusta, GANPI 1235545757

Payments from drug & device makers

$22,851in general payments, 2019–2025

Across 545 payments — averaging $41.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$8K
  • Shockwave Medical, Inc$2K
  • Penumbra, Inc.$2K
  • Medtronic$1K
  • Terumo Medical Corporation$904
  • Cardiovascular Systems Inc.$877
  • plus $7K from 28 others

What the payments were for

  • Travel & lodging$4,54320%
  • Food & beverage$17,53777%
  • Education$7723%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$22,851 in reported general payments places this provider in the 95th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$354,841
Medicare patients
1,954
Services billed
5,897

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban158$199,551
EntrestoSacubitril/Valsartan102$133,361
Repatha SureclickEvolocumab26$42,612
JardianceEmpagliflozin29$27,623
XareltoRivaroxaban27$26,782
FarxigaDapagliflozin Propanediol34$25,435
BrilintaTicagrelor23$24,029
Metoprolol Succinate227$2,819
Ranolazine ErRanolazine23$2,227
ClopidogrelClopidogrel Bisulfate175$1,849
Amiodarone Hcl35$1,439
Colchicine14$1,114
Diltiazem 24hr Er (Cd)Diltiazem Hcl34$1,034
Atorvastatin Calcium123$813
Furosemide166$770

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$305$199,551158 claims
NovartisEntresto$872$133,361102 claims
AstraZenecaFarxiga, Brilinta$339$49,46457 claims
Johnson & JohnsonXarelto$232$26,78227 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Augusta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →